What is tirzepatide?
Also known as: Mounjaro · Zepbound
- Route
- Subcutaneous
- Half-life
- ~5 days
- Evidence
- Strong evidence
Prescription dual GLP-1/GIP agonist sold as Mounjaro and Zepbound. Discussed around weight and blood sugar.
Tirzepatide is a prescription medication sold under the brand names Mounjaro and Zepbound. Unlike semaglutide, it acts on two receptors, GLP-1 and GIP, which is why it is often called a dual agonist.
It comes up most in conversations around weight and blood sugar, and it carries strong clinical evidence, giving it a Strong research tier in TRKD+.
Tirzepatide is prescription-only, so decisions about it and any dosing belong with a licensed provider. TRKD+ describes the compound and lets you track an existing regimen. It does not recommend or prescribe.
Vocabulary
Terms you’ll see with it.
- Protocol
GLP-1 agonist
A class of drugs (semaglutide, tirzepatide) that mimic a gut hormone tied to appetite.
- Protocol
Titration
Easing a dose up or down gradually over weeks, rather than jumping straight to a target.
- Route
Subcutaneous
Injected into the fat layer just under the skin. Short needle, shallow angle.
- Timing
Half-life
How long it takes for half of a dose to clear your system. Drives dosing frequency.
Common questions
People also ask.
- Is tirzepatide the same as Mounjaro and Zepbound?
- Yes, those are brand names for tirzepatide.
- How is tirzepatide different from semaglutide?
- Semaglutide activates the GLP-1 receptor; tirzepatide activates both GLP-1 and GIP, so it is called a dual agonist.
TRKD+
Track the whole stack, calmly.
Log peptides, GLP-1s, and TRT. Rotate injection sites. Free, private, no ads.